Citius Pharmaceuticals Aktie

Citius Pharmaceuticals für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A2DXS0 / ISIN: US17322U2078

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
09.06.2025 15:19:44

Citius Oncology Inks Distribution Services Agreement With Cardinal Health For LYMPHIR

(RTTNews) - Citius Oncology, Inc. (CTOR), the oncology-focused subsidiary of late-stage biopharmaceutical company Citius Pharmaceuticals, Inc. (CTXR), announced Monday it has entered into a distribution services agreement with Cardinal Health, Inc. (CAH) that supports the upcoming launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma.

This agreement is designed to help provide access to LYMPHIR (denileukin diftitox-cxdl), an innovative immunotherapy FDA-approved for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), in support of its anticipated U.S. commercial launch.

Cardinal Health's proven distribution capabilities will help ensure LYMPHIR reaches healthcare providers and patients efficiently and reliably, as Citius Oncology works to build a robust commercial distribution network.

Under the agreement, Cardinal Health will serve as an authorized distributor of record for Citius Oncology providing specialty pharmaceutical distribution services.

Nachrichten zu Citius Pharmaceuticals Inc Registered Shsmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Cardinal Health Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Cardinal Health Inc. 132,15 -2,15% Cardinal Health Inc.
Citius Oncology Inc Registered Shs 1,89 0,53% Citius Oncology Inc Registered Shs